108 results
Page 2 of 6
8-K
EX-99.1
tzi0cgu1eua9adx7a
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
i8ijv1hf1t se9
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-99.1
chcian0lviab 8w
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
8-K
EX-1.1
3w5srihozez8v2y9vh2x
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
424B5
v1q2ayu 3ypx
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
snc4 tzip
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
mxi6 yv8n
13 Sep 22
POINT Biopharma Announces Proposed Public Offering of Common Stock
4:12pm
8-K
EX-99.1
5wfjjw80tcnofk1
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.1
j8kgwbvxnp1y4
6 Sep 22
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
8:11am
424B3
9rwnecal
11 Jul 22
Prospectus supplement
4:32pm
POS AM
impm1jyga061
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
EX-1.2
iz8flpli
1 Jul 22
Shelf registration
4:13pm
S-3
3grt57jy i6
1 Jul 22
Shelf registration
4:13pm
424B3
EX-99.1
6b4hetqejyn
16 May 22
Prospectus supplement
8:27am